Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

NewsGuard 100/100 Score

Biogen Idec Inc. (NASDAQ:BIIB) today reiterated its proposal to acquire all of the outstanding shares of Facet Biotech Corporation for $14.50 per share in cash.

James C. Mullen, Biogen Idec’s President and Chief Executive Officer, stated, “We continue to believe that Biogen Idec’s $14.50 per share, all-cash offer represents an extremely attractive opportunity for Facet’s shareholders to realize today the future value of their company. The price we are offering ascribes meaningful and appropriate value to the company’s clinical programs while taking into account Facet’s significant building lease and other obligations, and recently announced collaboration agreement with Trubion. As such, we were disappointed to learn that Facet’s Board of Directors rejected our proposal without discussing its merits with us and our advisors. While we continue to urge Facet's Board to meet with us to conclude a definitive merger agreement, we are reviewing our options.”

Biogen Idec’s proposal is not subject to any financing contingency or approval by Biogen Idec shareholders. As announced on September 4, 2009, Biogen Idec’s all-cash offer represented a premium of approximately 64% over the $8.82 closing price of Facet’s common stock on September 3, 2009.

Biogen Idec and Facet have been working together since 2005 under a collaboration agreement pursuant to which they have been jointly developing daclizumab for the treatment of relapsing multiple sclerosis and volociximab (M200) for the treatment of solid tumors.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.